Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests

Nir Eyal; Tobias Gerhard; Brian L Strom

doi:10.1016/j.vaccine.2021.04.056

Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests

Vaccine. 2021 Jun 11;39(26):3455-3458. doi: 10.1016/j.vaccine.2021.04.056. Epub 2021 Apr 30.

Authors

Nir Eyal¹, Tobias Gerhard², Brian L Strom³

Affiliations

¹ Center for Population-Level Bioethics and Department of Philosophy, Rutgers University, New Brunswick, NJ, USA, Department of Health Behavior, Society and Policy, Rutgers School of Public Health, Piscataway, NJ, USA; Rutgers Biomedical and Health Sciences, Newark, NJ, USA.
² Center for Pharmacoepidemiology and Treatment Science, Rutgers University, New Brunswick, NJ, USA, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA; Rutgers Biomedical and Health Sciences, Newark, NJ, USA.
³ Rutgers Biomedical and Health Sciences, Newark, NJ, USA. Electronic address: bstrom@rbhs.rutgers.edu.

No abstract available

Keywords: Antibody dependent enhancement; Assessment, Risk benefit; Coronavirus; Ethics; Pharmacoepidemiology; Randomized clinical trials; Toxicity; Vaccines.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 Vaccines
COVID-19*
Humans
Prior Authorization
SARS-CoV-2
Viral Vaccines*

Substances

COVID-19 Vaccines
Viral Vaccines

Publication types

MeSH terms

Substances

Grants and funding